ONO PHARMACEUTICAL : Enters into Collaboration Agreement with Cyclenium Pharma, Inc. (33.8KB)

December 12, 2017

Ono Enters into Collaboration Agreement with Cyclenium Pharma, Inc.

Ono Pharmaceutical Co., Ltd. (Osaka Japan; President, Representative Director and CEO, Gyo Sagara; "Ono") announced today that Ono and Cyclenium Pharma, Inc. (Montreal, Quebec, Canada; Helmut Thomas, Ph.D., President, Chief Executive Officer & Chief Scientific Officer; "Cyclenium") signed a collaboration agreement, exploiting Cyclenium's proprietary CMRTTM Technology and QUEST Library™ of next generation synthetic small-molecule macrocycles.

In this collaboration, Ono will screen QUEST Library against multiple therapeutic targets selected by Ono in our therapeutic focus areas. Cyclenium will be responsible for all medicinal chemistry efforts, starting from hit validation, to generate new macrocyclic compounds by utilizing its CMRTTM Technology, while Ono will utilize its internal resources for the characterization of biological and pharmacological properties of these new macrocycles generated by Cyclenium, as well as having full rights and responsibility for development and commercialization of the resulting drug candidates worldwide. In return, Cyclenium will receive an upfront payment and research funding from Ono, as well as development milestones and royalties on marketed products.

"We highly appreciate Cyclenium's expertise in the macrocycle area and their technology platform to generate new drug candidate for high priority targets in our portfolio," said Hiromu Habashita, Ph.D., Corporate Officer and Executive Director, Discovery and Research of Ono. "We are very pleased to work with Cyclenium on identifying and developing the next generation of innovative drugs and we believe novel macrocyclic drugs to be generated through this collaboration will fulfill unmet medical needs"

"We are very excited about entering this collaboration with Ono, our second with a major, globally-operating, Japanese pharmaceutical partner," stated Helmut Thomas, Ph.D., President, Chief Executive Officer & Chief Scientific Officer of Cyclenium. "We are confident that our CMRT™ Technology and proven success in the macrocycle area combined with the excellent research team at Ono will provide new insight into the modulation of their difficult targets and enable the discovery of novel macrocyclic therapeutic agents."

About Cyclinium Pharma, Inc

Cyclenium Pharma is an emerging, privately-held pharmaceutical research and development company exploiting its proprietary next generation CMRT™ macrocyclic drug discovery technology for the discovery and development of novel small molecule therapeutic agents to address areas of unsatisfied medical need. Cyclenium is creating value through progression of internal programs in oncology, infectious diseases and inflammation/pain. In addition, Cyclenium is providing its extensive experience and exploring its CMRT-based QUEST™ screening library in risk-sharing partnerships with leading academic and research driven non-profit organizations, as well as collaborations with innovative pharmaceutical and biotechnology companies world-wide seeking to modulate unique and difficult disease targets in diverse therapeutic areas. For more information see:www.cyclenium.com.

Contact

ONO PHARMACEUTICAL CO., LTD. Corporate Communicationspublic_relations@ono.co.jp